newsfilter
← Latest News
Business Wire·

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene